The Patients' Access to Treatment Act (PATA) would significantly limit how much consumers pay for ???specialty tier??? ??? or Tier 4 ??? drugs, which include biologics that treat autoimmune forms of arthritis, as well as drugs for multiple sclerosis, cancer and other serious conditions.